Multimodal antidepressant
ATC code: N06AX26 (Vortioxetine)
Serotonin reuptake inhibition combined with 5-HT1A agonism, partial 5-HT1B agonism, and 5-HT3, 5-HT1D, and 5-HT7 antagonism. Multimodal action gives antidepressant effect with added cognitive improvement (attention, information processing) in depressed patients. Compared with SSRIs, less sexual dysfunction and fewer GI side effects. CYP2D6-metabolized, half-life 66 hours.
First line
First-line for major depressive disorder in adults per 2024 and the Spanish SEP 2024 alongside other modern antidepressants (SSRIs, SNRIs). Dose 5–20 mg once daily. Particularly suitable in patients with cognitive complaints in depression and in those with marked SSRI sexual dysfunction. The Cipriani 2018 meta-analysis showed efficacy comparable to other antidepressants with better tolerability (5.2% dropout for adverse effects vs 7.7% with SSRIs).
Sources
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Vortioxetine is an antidepressant with a multimodal mechanism of action. It is prescribed for major depression ( 2022 and NG222 guidelines). The manufacturer promotes vortioxetine as a drug for improving cognitive function in patients with depression, and this idea has spilled over into marketing for healthy adults seeking better concentration. There are no clinical studies in people without depression, and the label does not mention cognitive improvement in non-depressed patients. The drug carries standard antidepressant risks: pronounced nausea (especially in the first weeks), sexual dysfunction, discontinuation syndrome, and increased suicide risk in young adults (FDA boxed warning). If vortioxetine was prescribed for concentration improvement or brain function outside a depression indication, consider seeking a second opinion.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Boxed warning
FDA boxed warning: antidepressants increase suicidal ideation and behavior risk in children, adolescents, and young adults under 24 during the first weeks. Careful mental status monitoring is needed.
Limited pregnancy data. T3 use linked to neonatal adaptation syndrome. Sertraline is preferred in pregnant patients with depression.
Limited data. Not recommended during lactation.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Vortioxetine is evaluated for the following indications with varying evidence strength: Major depressive disorder (evidence tier A), Memory and concentration enhancement (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Vortioxetine (≥ 1 in 100): Nausea (most common), Headache, Constipation or diarrhea, Dry mouth, Dizziness, Abnormal dreams. See the Safety section for uncommon and serious reactions.
FDA category C. Limited pregnancy data. T3 use linked to neonatal adaptation syndrome. Sertraline is preferred in pregnant patients with depression.
Limited data. Not recommended during lactation.
Vortioxetine is contraindicated in: Vortioxetine hypersensitivity; Concurrent MAO inhibitors or within 14 days of stopping; Pregnancy and lactation; Age under 18. Full list in the Safety section.
FDA boxed warning: antidepressants increase suicidal ideation and behavior risk in children, adolescents, and young adults under 24 during the first weeks. Careful mental status monitoring is needed.